Background
Kira Biotech is an emerging Australian biotechnology company developing precision-engineered antibody therapies to address high unmet needs in autoimmune and inflammatory diseases. Its lead candidate, KB-358, is an anti-interferon monoclonal antibody used to treat systemic lupus erythematosus with a superior risk/benefit profile.
Kira Biotech has attracted venture capital funding and is progressing KB-358 through a phase 2 adaptive trial with an experienced team of drug development experts led by US-based rheumatologist and immunologist, Dr. Dan Baker.
Back to Portfolio
Founded
Location
Industry
2019
Queensland, Australia
Biotech & Medtech
Dan Baker
Chief Executive Officer
